Acquired resistance to cancer immunotherapy

TY - JOUR

T1 - Acquired resistance to cancer immunotherapy

AU - Draghi, Arianna

AU - Chamberlain, Christopher Aled

AU - Furness, Andrew

AU - Donia, Marco

PY - 2019/1/11

Y1 - 2019/1/11

N2 - In recent times, advances in cancer immunotherapy have yielded impressive, durable clinical responses in patients with varied subtypes of cancer. However, a significant proportion of patients who initially demonstrate encouraging tumor regression develop resistance and progress over time. The identification of novel therapeutic approaches to overcome resistance may result in significantly improved clinical outcomes and remains an area of high scientific priority. This review aims to summarize the current knowledge regarding the role of both tumor-intrinsic and tumor-extrinsic factors in the development of resistance to cancer immunotherapy and to discuss current and possible future therapeutic strategies targeting these mechanisms.

AB - In recent times, advances in cancer immunotherapy have yielded impressive, durable clinical responses in patients with varied subtypes of cancer. However, a significant proportion of patients who initially demonstrate encouraging tumor regression develop resistance and progress over time. The identification of novel therapeutic approaches to overcome resistance may result in significantly improved clinical outcomes and remains an area of high scientific priority. This review aims to summarize the current knowledge regarding the role of both tumor-intrinsic and tumor-extrinsic factors in the development of resistance to cancer immunotherapy and to discuss current and possible future therapeutic strategies targeting these mechanisms.

U2 - 10.1007/s00281-018-0692-y

DO - 10.1007/s00281-018-0692-y

M3 - Review

C2 - 29968044

SN - 1863-2297

VL - 41

SP - 31

EP - 40

JO - Seminars in Immunopathology

JF - Seminars in Immunopathology

ER -